Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $2.04M |
| Net Income (Most Recent Fiscal Year) | $-162.34M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3337.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -12998.50% |
| Net Margin (Trailing 12 Months) | -12998.50% |
| Return on Equity (Trailing 12 Months) | -27.30% |
| Return on Assets (Trailing 12 Months) | -25.91% |
| Current Ratio (Most Recent Fiscal Quarter) | 29.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 29.25 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.85 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.20 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.67M |
| Free Float | 53.02M |
| Market Capitalization | $4.46B |
| Average Volume (Last 20 Days) | 0.56M |
| Beta (Past 60 Months) | 1.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.02% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |